In fiscal year 2023 — Oct. 1–Sept. 30, 2023 — Oak Ridge National Laboratory was awarded more than $8 million in technology maturation funding through the Department of Energy’s Technology Commercialization Fund, or TCF.
Few things carry the same aura of mystery as dark matter. The name itself radiates secrecy, suggesting something hidden in the shadows of the Universe.
Oak Ridge National Laboratory physicist Elizabeth “Libby” Johnson (1921-1996), one of the world’s first nuclear reactor operators, standardized the field of criticality safety with peers from ORNL and Los Alamos National Laboratory.
Scientists at ORNL used neutron scattering to determine whether a specific material’s atomic structure could host a novel state of matter called a spiral spin liquid.
To solve a long-standing puzzle about how long a neutron can “live” outside an atomic nucleus, physicists entertained a wild but testable theory positing the existence of a right-handed version of our left-handed universe.
ORNL and the Tennessee Valley Authority, or TVA, are joining forces to advance decarbonization technologies from discovery through deployment through a new memorandum of understanding, or MOU.
More than 50 current employees and recent retirees from ORNL received Department of Energy Secretary’s Honor Awards from Secretary Jennifer Granholm in January as part of project teams spanning the national laboratory system. The annual awards recognized 21 teams and three individuals for service and contributions to DOE’s mission and to the benefit of the nation.
Three ORNL scientists have been elected fellows of the American Association for the Advancement of Science, or AAAS, the world’s largest general scientific society and publisher of the Science family of journals.
A team led by the U.S. Department of Energy’s Oak Ridge National Laboratory demonstrated the viability of a “quantum entanglement witness” capable of proving the presence of entanglement between magnetic particles, or spins, in a quantum material.
An ORNL-led team comprising researchers from multiple DOE national laboratories is using artificial intelligence and computational screening techniques – in combination with experimental validation – to identify and design five promising drug therapy approaches to target the SARS-CoV-2 virus.